Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | HSPA4L | Human | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSPA4L mRNA | CTD | PMID:22079256 | HSPA4L | Human | (1->4)-beta-D-glucan | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of HSPA4L mRNA | CTD | PMID:36331819 | HSPA4L | Human | 17alpha-ethynylestradiol | affects expression | ISO | Hspa4l (Mus musculus) | 6480464 | Ethinyl Estradiol affects the expression of HSPA4L mRNA | CTD | PMID:17555576 | HSPA4L | Human | 17alpha-ethynylestradiol | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of HSPA4L mRNA | CTD | PMID:17942748 | HSPA4L | Human | 17alpha-ethynylestradiol | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Ethinyl Estradiol results in increased expression of HSPA4L mRNA | CTD | PMID:17942748 | HSPA4L | Human | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of HSPA4L mRNA | CTD | PMID:20106945 | HSPA4L | Human | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [Estradiol co-treated with TGFB1 protein] results in decreased expression of HSPA4L mRNA | CTD | PMID:30165855 | HSPA4L | Human | 1H-pyrazole | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | pyrazole results in increased expression of HSPA4L mRNA | CTD | PMID:17945193 | HSPA4L | Human | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of HSPA4L mRNA | CTD | PMID:17942748 | HSPA4L | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of HSPA4L mRNA | CTD | PMID:33387578 | HSPA4L | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of HSPA4L mRNA | CTD | PMID:32109520 | HSPA4L | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of HSPA4L mRNA | CTD | PMID:18691609 more ... | HSPA4L | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Hspa4l (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of HSPA4L mRNA | CTD | PMID:21570461 | HSPA4L | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of HSPA4L mRNA | CTD | PMID:20106945 and PMID:21632981 | HSPA4L | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of HSPA4L mRNA | CTD | PMID:22298810 | HSPA4L | Human | 2,4-dinitrotoluene | affects expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | 2 and 4-dinitrotoluene affects the expression of HSPA4L mRNA | CTD | PMID:21346803 | HSPA4L | Human | 2-butoxyethanol | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | n-butoxyethanol results in increased expression of HSPA4L mRNA | CTD | PMID:19812364 | HSPA4L | Human | 3,3',4,4',5-pentachlorobiphenyl | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | 3 more ... | CTD | PMID:23994337 | HSPA4L | Human | 3,4-methylenedioxymethamphetamine | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in decreased expression of HSPA4L mRNA | CTD | PMID:26251327 | HSPA4L | Human | 4,4'-diaminodiphenylmethane | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | 4 and 4'-diaminodiphenylmethane results in increased expression of HSPA4L mRNA | CTD | PMID:18648102 | HSPA4L | Human | 4-hydroxynon-2-enal | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | 4-hydroxy-2-nonenal results in increased expression of HSPA4L mRNA | CTD | PMID:19191707 | HSPA4L | Human | 4-hydroxyphenyl retinamide | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Fenretinide results in decreased expression of HSPA4L mRNA | CTD | PMID:28973697 | HSPA4L | Human | 4-phenylbutyric acid | increases expression | EXP | | 6480464 | 4-phenylbutyric acid results in increased expression of HSPA4L mRNA | CTD | PMID:14583596 | HSPA4L | Human | 6-propyl-2-thiouracil | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Propylthiouracil results in decreased expression of HSPA4L mRNA | CTD | PMID:24780913 | HSPA4L | Human | aconitine | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Aconitine results in increased expression of HSPA4L protein | CTD | PMID:33236894 | HSPA4L | Human | acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of HSPA4L mRNA | CTD | PMID:32763439 | HSPA4L | Human | actinomycin D | multiple interactions | EXP | | 6480464 | [Dactinomycin co-treated with nutlin 3] results in increased expression of HSPA4L mRNA and [Dactinomycin co-treated with nutlin 3] results in increased secretion of HSPA4L protein | CTD | PMID:38460933 | HSPA4L | Human | aflatoxin B1 | affects expression | EXP | | 6480464 | Aflatoxin B1 affects the expression of HSPA4L protein | CTD | PMID:20106945 | HSPA4L | Human | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of HSPA4L mRNA | CTD | PMID:21641981 more ... | HSPA4L | Human | aflatoxin B1 | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Aflatoxin B1 results in increased expression of HSPA4L mRNA | CTD | PMID:19770486 | HSPA4L | Human | aflatoxin M1 | decreases expression | EXP | | 6480464 | Aflatoxin M1 results in decreased expression of HSPA4L mRNA | CTD | PMID:30928695 | HSPA4L | Human | all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of HSPA4L mRNA | CTD | PMID:21934132 | HSPA4L | Human | all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of HSPA4L mRNA | CTD | PMID:23724009 and PMID:33167477 | HSPA4L | Human | antirheumatic drug | decreases expression | EXP | | 6480464 | Antirheumatic Agents results in decreased expression of HSPA4L mRNA | CTD | PMID:24449571 | HSPA4L | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of HSPA4L mRNA | CTD | PMID:33212167 | HSPA4L | Human | arsenite(3-) | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [arsenite co-treated with Benzo(a)pyrene] results in increased expression of HSPA4L mRNA | CTD | PMID:15894712 | HSPA4L | Human | arsenite(3-) | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | arsenite results in increased expression of HSPA4L mRNA | CTD | PMID:15894712 | HSPA4L | Human | arsenous acid | increases expression | EXP | | 6480464 | Arsenic Trioxide results in increased expression of HSPA4L mRNA | CTD | PMID:26705709 | HSPA4L | Human | benzo[a]pyrene | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [arsenite co-treated with Benzo(a)pyrene] results in increased expression of HSPA4L mRNA and [Potassium Dichromate co-treated with potassium chromate(VI)] inhibits the reaction [Benzo(a)pyrene results in increased expression of HSPA4L mRNA] | CTD | PMID:14625279 and PMID:15894712 | HSPA4L | Human | benzo[a]pyrene | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of HSPA4L mRNA | CTD | PMID:14625279 more ... | HSPA4L | Human | benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of HSPA4L mRNA and Benzo(a)pyrene results in increased expression of HSPA4L protein | CTD | PMID:20106945 more ... | HSPA4L | Human | beta-naphthoflavone | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | beta-Naphthoflavone results in increased expression of HSPA4L mRNA | CTD | PMID:23994337 | HSPA4L | Human | bis(2-ethylhexyl) phthalate | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Diethylhexyl Phthalate results in decreased expression of HSPA4L mRNA | CTD | PMID:21318169 | HSPA4L | Human | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of HSPA4L mRNA | CTD | PMID:29275510 | HSPA4L | Human | bisphenol A | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of HSPA4L mRNA | CTD | PMID:30816183 and PMID:34947998 | HSPA4L | Human | bisphenol F | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | bisphenol F results in increased expression of HSPA4L mRNA | CTD | PMID:38685157 | HSPA4L | Human | bortezomib | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Bortezomib results in increased expression of HSPA4L mRNA | CTD | PMID:20830808 | HSPA4L | Human | Brodifacoum | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | bromfenacoum results in increased expression of HSPA4L protein | CTD | PMID:28903499 | HSPA4L | Human | bromobenzene | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | bromobenzene results in decreased expression of HSPA4L mRNA | CTD | PMID:32479839 | HSPA4L | Human | cadmium atom | increases expression | EXP | | 6480464 | Cadmium results in increased expression of HSPA4L mRNA | CTD | PMID:21120746 | HSPA4L | Human | cadmium atom | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of HSPA4L mRNA | CTD | PMID:37325564 | HSPA4L | Human | cadmium dichloride | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Cadmium Chloride results in increased expression of HSPA4L mRNA | CTD | PMID:15501611 | HSPA4L | Human | cadmium dichloride | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of HSPA4L mRNA | CTD | PMID:37325564 | HSPA4L | Human | caffeine | decreases phosphorylation | EXP | | 6480464 | Caffeine results in decreased phosphorylation of HSPA4L protein | CTD | PMID:35688186 | HSPA4L | Human | carbamazepine | affects expression | EXP | | 6480464 | Carbamazepine affects the expression of HSPA4L mRNA | CTD | PMID:25979313 | HSPA4L | Human | carbon nanotube | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 and PMID:25620056 | HSPA4L | Human | chlorpyrifos | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Chlorpyrifos results in decreased expression of HSPA4L mRNA | CTD | PMID:37019170 | HSPA4L | Human | choline | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of HSPA4L gene | CTD | PMID:20938992 | HSPA4L | Human | chromium(6+) | affects expression | EXP | | 6480464 | chromium hexavalent ion affects the expression of HSPA4L mRNA | CTD | PMID:30690063 | HSPA4L | Human | ciguatoxin CTX1B | affects expression | ISO | Hspa4l (Mus musculus) | 6480464 | Ciguatoxins affects the expression of HSPA4L mRNA | CTD | PMID:18353800 | HSPA4L | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Piroxicam co-treated with Cisplatin] results in increased expression of HSPA4L mRNA | CTD | PMID:21858171 | HSPA4L | Human | clofibrate | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Clofibrate results in increased expression of HSPA4L mRNA | CTD | PMID:23811191 | HSPA4L | Human | copper(II) sulfate | decreases expression | EXP | | 6480464 | Copper Sulfate results in decreased expression of HSPA4L mRNA | CTD | PMID:19549813 | HSPA4L | Human | coumestrol | increases expression | EXP | | 6480464 | Coumestrol results in increased expression of HSPA4L mRNA | CTD | PMID:19167446 | HSPA4L | Human | coumestrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HSPA4L mRNA | CTD | PMID:19167446 | HSPA4L | Human | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of HSPA4L mRNA | CTD | PMID:20106945 | HSPA4L | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of HSPA4L mRNA | CTD | PMID:27989131 | HSPA4L | Human | cyclosporin A | affects expression | EXP | | 6480464 | Cyclosporine affects the expression of HSPA4L mRNA | CTD | PMID:25562108 | HSPA4L | Human | DDE | increases expression | EXP | | 6480464 | Dichlorodiphenyl Dichloroethylene results in increased expression of HSPA4L mRNA | CTD | PMID:38568856 | HSPA4L | Human | diarsenic trioxide | increases expression | EXP | | 6480464 | Arsenic Trioxide results in increased expression of HSPA4L mRNA | CTD | PMID:26705709 | HSPA4L | Human | dibenz[a,h]anthracene | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | 1 more ... | CTD | PMID:26377693 | HSPA4L | Human | dibenzo[a,l]pyrene | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | dibenzo(a and l)pyrene results in decreased expression of HSPA4L mRNA | CTD | PMID:25908611 | HSPA4L | Human | dimethylarsinic acid | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPA4L mRNA] | CTD | PMID:17441966 | HSPA4L | Human | dimethylarsinic acid | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Cacodylic Acid results in decreased expression of HSPA4L mRNA | CTD | PMID:17441966 | HSPA4L | Human | dioxygen | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Oxygen deficiency results in decreased expression of HSPA4L mRNA | CTD | PMID:26476374 | HSPA4L | Human | dioxygen | multiple interactions | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Quercetin inhibits the reaction [Oxygen deficiency results in decreased expression of HSPA4L mRNA] | CTD | PMID:26476374 | HSPA4L | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | HSPA4L | Human | doxorubicin | affects expression | EXP | | 6480464 | Doxorubicin affects the expression of HSPA4L mRNA | CTD | PMID:25529476 | HSPA4L | Human | doxorubicin | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Doxorubicin results in decreased expression of HSPA4L mRNA | CTD | PMID:30261314 | HSPA4L | Human | endosulfan | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Endosulfan results in increased expression of HSPA4L mRNA | CTD | PMID:29391264 | HSPA4L | Human | Enterolactone | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HSPA4L mRNA | CTD | PMID:19167446 | HSPA4L | Human | entinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA | CTD | PMID:27188386 | HSPA4L | Human | entinostat | increases expression | EXP | | 6480464 | entinostat results in increased expression of HSPA4L mRNA | CTD | PMID:26272509 | HSPA4L | Human | enzyme inhibitor | multiple interactions | EXP | | 6480464 | [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of HSPA4L protein | CTD | PMID:23301498 | HSPA4L | Human | epoxiconazole | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | epoxiconazole results in decreased expression of HSPA4L mRNA | CTD | PMID:35436446 | HSPA4L | Human | ethanol | multiple interactions | EXP | | 6480464 | [Ethanol co-treated with Folic Acid] results in increased expression of HSPA4L mRNA | CTD | PMID:23378141 | HSPA4L | Human | ethanol | affects splicing | ISO | Hspa4l (Mus musculus) | 6480464 | Ethanol affects the splicing of HSPA4L mRNA | CTD | PMID:30319688 | HSPA4L | Human | ethanol | increases expression | EXP | | 6480464 | Ethanol results in increased expression of HSPA4L mRNA | CTD | PMID:23378141 and PMID:28986285 | HSPA4L | Human | fenofibrate | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Fenofibrate results in increased expression of HSPA4L mRNA | CTD | PMID:21318169 | HSPA4L | Human | fenofibrate | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | PPARA protein affects the reaction [Fenofibrate results in increased expression of HSPA4L mRNA] | CTD | PMID:21318169 | HSPA4L | Human | fenvalerate | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | fenvalerate results in decreased expression of HSPA4L protein | CTD | PMID:33656234 | HSPA4L | Human | flutamide | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Flutamide results in decreased expression of HSPA4L mRNA | CTD | PMID:24793618 | HSPA4L | Human | folic acid | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of HSPA4L gene | CTD | PMID:20938992 | HSPA4L | Human | folic acid | multiple interactions | EXP | | 6480464 | [Ethanol co-treated with Folic Acid] results in increased expression of HSPA4L mRNA | CTD | PMID:23378141 | HSPA4L | Human | furan | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | furan results in increased expression of HSPA4L mRNA | CTD | PMID:24183702 | HSPA4L | Human | furan | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | furan results in increased expression of HSPA4L mRNA | CTD | PMID:25539665 | HSPA4L | Human | genistein | increases expression | EXP | | 6480464 | Genistein results in increased expression of HSPA4L mRNA | CTD | PMID:18847459 | HSPA4L | Human | gentamycin | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Gentamicins results in decreased expression of HSPA4L mRNA | CTD | PMID:22061828 | HSPA4L | Human | gentamycin | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Gentamicins results in increased expression of HSPA4L mRNA | CTD | PMID:33387578 | HSPA4L | Human | hydrogen cyanide | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Hydrogen Cyanide results in increased expression of HSPA4L mRNA | CTD | PMID:33914522 | HSPA4L | Human | hydrogen sulfide | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Hydrogen Sulfide results in decreased expression of HSPA4L protein | CTD | PMID:29932956 | HSPA4L | Human | irinotecan | decreases expression | EXP | | 6480464 | Irinotecan metabolite results in decreased expression of HSPA4L mRNA and Irinotecan results in decreased expression of HSPA4L mRNA | CTD | PMID:15956246 | HSPA4L | Human | ivermectin | decreases expression | EXP | | 6480464 | Ivermectin results in decreased expression of HSPA4L protein | CTD | PMID:32959892 | HSPA4L | Human | L-methionine | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of HSPA4L gene | CTD | PMID:20938992 | HSPA4L | Human | leflunomide | increases expression | EXP | | 6480464 | leflunomide results in increased expression of HSPA4L mRNA | CTD | PMID:28988120 | HSPA4L | Human | manganese(II) chloride | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | manganese chloride results in increased expression of HSPA4L mRNA | CTD | PMID:28801915 | HSPA4L | Human | mercury dibromide | increases expression | EXP | | 6480464 | mercuric bromide results in increased expression of HSPA4L mRNA | CTD | PMID:26272509 | HSPA4L | Human | mercury dibromide | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA | CTD | PMID:27188386 | HSPA4L | Human | mercury dichloride | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Mercuric Chloride results in increased expression of HSPA4L mRNA | CTD | PMID:16507785 | HSPA4L | Human | methidathion | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | methidathion results in decreased expression of HSPA4L mRNA | CTD | PMID:34813904 | HSPA4L | Human | methyl methanesulfonate | increases expression | EXP | | 6480464 | Methyl Methanesulfonate results in increased expression of HSPA4L mRNA | CTD | PMID:23649840 | HSPA4L | Human | methylisothiazolinone | increases expression | EXP | | 6480464 | 2-methyl-4-isothiazolin-3-one results in increased expression of HSPA4L mRNA | CTD | PMID:31629900 | HSPA4L | Human | methylmercury chloride | increases expression | EXP | | 6480464 | methylmercuric chloride results in increased expression of HSPA4L mRNA | CTD | PMID:28001369 | HSPA4L | Human | methylseleninic acid | increases expression | EXP | | 6480464 | methylselenic acid results in increased expression of HSPA4L mRNA | CTD | PMID:18548127 | HSPA4L | Human | motexafin gadolinium | increases expression | EXP | | 6480464 | motexafin gadolinium results in increased expression of HSPA4L mRNA | CTD | PMID:16357179 | HSPA4L | Human | motexafin gadolinium | multiple interactions | EXP | | 6480464 | [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4L mRNA | CTD | PMID:16357179 | HSPA4L | Human | N-methyl-4-phenylpyridinium | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | 1-Methyl-4-phenylpyridinium results in increased expression of HSPA4L mRNA | CTD | PMID:28801915 | HSPA4L | Human | N-nitrosodiethylamine | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Diethylnitrosamine results in increased expression of HSPA4L mRNA | CTD | PMID:24535843 | HSPA4L | Human | Nonidet P-40 | increases expression | EXP | | 6480464 | Nonidet P-40 results in increased expression of HSPA4L mRNA | CTD | PMID:26552463 | HSPA4L | Human | Nutlin-3 | multiple interactions | EXP | | 6480464 | [Dactinomycin co-treated with nutlin 3] results in increased expression of HSPA4L mRNA and [Dactinomycin co-treated with nutlin 3] results in increased secretion of HSPA4L protein | CTD | PMID:38460933 | HSPA4L | Human | p-chloromercuribenzoic acid | increases expression | EXP | | 6480464 | p-Chloromercuribenzoic Acid results in increased expression of HSPA4L mRNA | CTD | PMID:26272509 | HSPA4L | Human | p-chloromercuribenzoic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA | CTD | PMID:27188386 | HSPA4L | Human | panobinostat | increases expression | EXP | | 6480464 | panobinostat results in increased expression of HSPA4L mRNA | CTD | PMID:26272509 | HSPA4L | Human | panobinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA | CTD | PMID:27188386 | HSPA4L | Human | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of HSPA4L mRNA | CTD | PMID:21420995 more ... | HSPA4L | Human | paracetamol | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Acetaminophen results in increased expression of HSPA4L mRNA | CTD | PMID:33387578 | HSPA4L | Human | perfluorohexanesulfonic acid | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | perfluorohexanesulfonic acid results in increased expression of HSPA4L mRNA | CTD | PMID:37995155 | HSPA4L | Human | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of HSPA4L mRNA and [perfluorooctane sulfonic acid co-treated with Pectins] results in increased expression of HSPA4L mRNA | CTD | PMID:36331819 | HSPA4L | Human | phenformin | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Phenformin results in decreased expression of HSPA4L mRNA | CTD | PMID:31324951 | HSPA4L | Human | phenobarbital | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | NR1I3 protein affects the reaction [Phenobarbital results in increased expression of HSPA4L mRNA] | CTD | PMID:19482888 | HSPA4L | Human | phenobarbital | affects expression | ISO | Hspa4l (Mus musculus) | 6480464 | Phenobarbital affects the expression of HSPA4L mRNA | CTD | PMID:23091169 | HSPA4L | Human | phenobarbital | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Phenobarbital results in increased expression of HSPA4L mRNA | CTD | PMID:19482888 | HSPA4L | Human | phenylmercury acetate | increases expression | EXP | | 6480464 | Phenylmercuric Acetate results in increased expression of HSPA4L mRNA | CTD | PMID:26272509 | HSPA4L | Human | phenylmercury acetate | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA | CTD | PMID:27188386 | HSPA4L | Human | pirinixic acid | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | PPARA protein affects the reaction [pirinixic acid results in increased expression of HSPA4L mRNA] and PPARA protein promotes the reaction [pirinixic acid results in increased expression of HSPA4L mRNA] | CTD | PMID:20059764 and PMID:21318169 | HSPA4L | Human | pirinixic acid | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | pirinixic acid results in increased expression of HSPA4L mRNA | CTD | PMID:18301758 more ... | HSPA4L | Human | piroxicam | multiple interactions | EXP | | 6480464 | [Piroxicam co-treated with Cisplatin] results in increased expression of HSPA4L mRNA | CTD | PMID:21858171 | HSPA4L | Human | potassium chromate | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [Potassium Dichromate co-treated with potassium chromate(VI)] inhibits the reaction [Benzo(a)pyrene results in increased expression of HSPA4L mRNA] | CTD | PMID:14625279 | HSPA4L | Human | potassium chromate | increases expression | EXP | | 6480464 | potassium chromate(VI) results in increased expression of HSPA4L mRNA | CTD | PMID:22714537 | HSPA4L | Human | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSPA4L mRNA | CTD | PMID:22079256 | HSPA4L | Human | potassium chromate | decreases expression | EXP | | 6480464 | potassium chromate(VI) results in decreased expression of HSPA4L mRNA | CTD | PMID:22079256 | HSPA4L | Human | potassium cyanide | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Potassium Cyanide results in increased expression of HSPA4L mRNA | CTD | PMID:33914522 | HSPA4L | Human | potassium dichromate | multiple interactions | ISO | Hspa4l (Mus musculus) | 6480464 | [Potassium Dichromate co-treated with potassium chromate(VI)] inhibits the reaction [Benzo(a)pyrene results in increased expression of HSPA4L mRNA] | CTD | PMID:14625279 | HSPA4L | Human | progesterone | affects expression | ISO | Hspa4l (Mus musculus) | 6480464 | Progesterone affects the expression of HSPA4L mRNA | CTD | PMID:17251523 | HSPA4L | Human | propiconazole | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | propiconazole results in increased expression of HSPA4L mRNA | CTD | PMID:21278054 | HSPA4L | Human | propiconazole | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | propiconazole results in increased expression of HSPA4L mRNA | CTD | PMID:16643972 | HSPA4L | Human | quercetin | multiple interactions | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Quercetin inhibits the reaction [Oxygen deficiency results in decreased expression of HSPA4L mRNA] | CTD | PMID:26476374 | HSPA4L | Human | quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of HSPA4L mRNA | CTD | PMID:21632981 | HSPA4L | Human | resorcinol | decreases expression | EXP | | 6480464 | resorcinol results in decreased expression of HSPA4L mRNA | CTD | PMID:22623647 | HSPA4L | Human | resveratrol | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | resveratrol results in increased expression of HSPA4L protein | CTD | PMID:25505154 | HSPA4L | Human | retinyl acetate | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | retinol acetate results in increased expression of HSPA4L mRNA | CTD | PMID:16772331 | HSPA4L | Human | rotenone | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Rotenone results in decreased expression of HSPA4L mRNA | CTD | PMID:28374803 | HSPA4L | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | HSPA4L | Human | silver atom | increases expression | EXP | | 6480464 | Silver results in increased expression of HSPA4L mRNA | CTD | PMID:26014281 and PMID:28959546 | HSPA4L | Human | silver(0) | increases expression | EXP | | 6480464 | Silver results in increased expression of HSPA4L mRNA | CTD | PMID:26014281 and PMID:28959546 | HSPA4L | Human | sodium arsenite | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | sodium arsenite results in increased expression of HSPA4L mRNA | CTD | PMID:16014739 | HSPA4L | Human | sodium arsenite | increases expression | EXP | | 6480464 | sodium arsenite results in increased expression of HSPA4L mRNA | CTD | PMID:26535918 and PMID:34032870 | HSPA4L | Human | tamoxifen | affects expression | ISO | Hspa4l (Mus musculus) | 6480464 | Tamoxifen affects the expression of HSPA4L mRNA | CTD | PMID:17555576 and PMID:20937368 | HSPA4L | Human | temozolomide | increases expression | EXP | | 6480464 | Temozolomide results in increased expression of HSPA4L mRNA | CTD | PMID:31758290 | HSPA4L | Human | tetrachloromethane | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Carbon Tetrachloride results in increased expression of HSPA4L mRNA | CTD | PMID:27339419 and PMID:31919559 | HSPA4L | Human | thimerosal | increases expression | EXP | | 6480464 | Thimerosal results in increased expression of HSPA4L mRNA | CTD | PMID:27188386 | HSPA4L | Human | thioacetamide | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Thioacetamide results in increased expression of HSPA4L mRNA | CTD | PMID:23411599 and PMID:34492290 | HSPA4L | Human | titanium dioxide | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of HSPA4L mRNA | CTD | PMID:23557971 | HSPA4L | Human | titanium dioxide | increases methylation | ISO | Hspa4l (Mus musculus) | 6480464 | titanium dioxide results in increased methylation of HSPA4L gene and titanium dioxide results in increased methylation of HSPA4L promoter | CTD | PMID:35295148 | HSPA4L | Human | triadimefon | decreases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | triadimefon results in decreased expression of HSPA4L mRNA | CTD | PMID:16643972 | HSPA4L | Human | trichloroethene | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | Trichloroethylene results in increased expression of HSPA4L mRNA | CTD | PMID:33387578 | HSPA4L | Human | trichostatin A | increases expression | EXP | | 6480464 | trichostatin A results in increased expression of HSPA4L mRNA | CTD | PMID:24935251 and PMID:26272509 | HSPA4L | Human | trichostatin A | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA | CTD | PMID:27188386 | HSPA4L | Human | Triptolide | affects expression | ISO | Hspa4l (Mus musculus) | 6480464 | triptolide affects the expression of HSPA4L mRNA | CTD | PMID:32835833 | HSPA4L | Human | triptonide | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | triptonide results in decreased expression of HSPA4L mRNA | CTD | PMID:33045310 | HSPA4L | Human | troglitazone | increases expression | ISO | Hspa4l (Mus musculus) | 6480464 | troglitazone results in increased expression of HSPA4L mRNA | CTD | PMID:28973697 | HSPA4L | Human | tungsten | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | Tungsten results in decreased expression of HSPA4L mRNA | CTD | PMID:30912803 | HSPA4L | Human | urethane | increases expression | EXP | | 6480464 | Urethane results in increased expression of HSPA4L mRNA | CTD | PMID:28818685 | HSPA4L | Human | valproic acid | affects expression | ISO | Hspa4l (Mus musculus) | 6480464 | Valproic Acid affects the expression of HSPA4L mRNA | CTD | PMID:17963808 | HSPA4L | Human | valproic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA | CTD | PMID:27188386 | HSPA4L | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of HSPA4L mRNA | CTD | PMID:23179753 more ... | HSPA4L | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of HSPA4L mRNA | CTD | PMID:25979313 | HSPA4L | Human | vinclozolin | decreases expression | ISO | Hspa4l (Mus musculus) | 6480464 | vinclozolin results in decreased expression of HSPA4L mRNA | CTD | PMID:18940246 | HSPA4L | Human | vinclozolin | increases expression | ISO | Hspa4l (Rattus norvegicus) | 6480464 | vinclozolin results in increased expression of HSPA4L mRNA | CTD | PMID:23034163 | HSPA4L | Human | vorinostat | increases expression | EXP | | 6480464 | vorinostat results in increased expression of HSPA4L mRNA | CTD | PMID:27188386 | HSPA4L | Human | zinc acetate | multiple interactions | EXP | | 6480464 | [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4L mRNA | CTD | PMID:16357179 | HSPA4L | Human | zinc acetate | increases expression | EXP | | 6480464 | Zinc Acetate results in increased expression of HSPA4L mRNA | CTD | PMID:16357179 | HSPA4L | Human | zinc atom | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of HSPA4L mRNA | CTD | PMID:18593933 | HSPA4L | Human | zinc(0) | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of HSPA4L mRNA | CTD | PMID:18593933 | |